These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15671744)

  • 1. Flavivirus immunization with capsid-deletion mutants: basics, benefits, and barriers.
    Mandl CW
    Viral Immunol; 2004; 17(4):461-72. PubMed ID: 15671744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mimicking live flavivirus immunization with a noninfectious RNA vaccine.
    Kofler RM; Aberle JH; Aberle SW; Allison SL; Heinz FX; Mandl CW
    Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1951-6. PubMed ID: 14769933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replication/Assembly Defective Avian Flavivirus With Internal Deletions in the Capsid Can Be Used as an Approach for Living Attenuated Vaccine.
    He Y; Wang X; Guo J; Mao L; Zhang S; Hu T; Wang M; Jia R; Zhu D; Liu M; Zhao X; Yang Q; Wu Y; Zhang S; Huang J; Mao S; Ou X; Gao Q; Sun D; Liu Y; Zhang L; Yu Y; Cheng A; Chen S
    Front Immunol; 2021; 12():694959. PubMed ID: 34421904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses.
    Widman DG; Frolov I; Mason PW
    Adv Virus Res; 2008; 72():77-126. PubMed ID: 19081489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel principle of attenuation for the development of new generation live flavivirus vaccines.
    Kofler RM; Heinz FX; Mandl CW
    Arch Virol Suppl; 2004; (18):191-200. PubMed ID: 15119774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence.
    Kofler RM; Heinz FX; Mandl CW
    J Virol; 2002 Apr; 76(7):3534-43. PubMed ID: 11884577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.
    Lai CJ; Monath TP
    Adv Virus Res; 2003; 61():469-509. PubMed ID: 14714441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.
    Aberle JH; Aberle SW; Kofler RM; Mandl CW
    J Virol; 2005 Dec; 79(24):15107-13. PubMed ID: 16306582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in flavivirus vaccine development.
    Coller BA; Clements DE; Martyak T; Yelmene M; Thorne M; Parks DE
    IDrugs; 2010 Dec; 13(12):880-4. PubMed ID: 21154147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live flavivirus vaccines: reasons for caution.
    Seligman SJ; Gould EA
    Lancet; 2004 Jun; 363(9426):2073-5. PubMed ID: 15207960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Internal Ribosome Entry Site/MicroRNA-Based Approach for Flavivirus Attenuation and Live Vaccine Development.
    Tsetsarkin KA; Liu G; Volkova E; Pletnev AG
    mBio; 2017 Apr; 8(2):. PubMed ID: 28420742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flaviviruses and flavivirus vaccines.
    Heinz FX; Stiasny K
    Vaccine; 2012 Jun; 30(29):4301-6. PubMed ID: 22682286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Traditional and novel approaches to flavivirus vaccines.
    Pugachev KV; Guirakhoo F; Trent DW; Monath TP
    Int J Parasitol; 2003 May; 33(5-6):567-82. PubMed ID: 12782056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Vaccination with a DNA Vaccine Encoding Capsid Protein of Duck Tembusu Virus Induces Protection Immunity.
    Huang J; Shen H; Jia R; Wang M; Chen S; Zhu D; Liu M; Zhao X; Yang Q; Wu Y; Liu Y; Zhang L; Yin Z; Jing B; Cheng A
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29642401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-based control of tick-borne flavivirus neuropathogenesis: Challenges and perspectives.
    Teterina NL; Maximova OA; Kenney H; Liu G; Pletnev AG
    Antiviral Res; 2016 Mar; 127():57-67. PubMed ID: 26794396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying Attenuating Mutations: Tools for a New Vaccine Design against Flaviviruses.
    Khou C; Pardigon N
    Intervirology; 2017; 60(1-2):8-18. PubMed ID: 28869941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advancement in flavivirus vaccine development.
    Chang GJ; Kuno G; Purdy DE; Davis BS
    Expert Rev Vaccines; 2004 Apr; 3(2):199-220. PubMed ID: 15056045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines.
    Eckels KH; Putnak R
    Adv Virus Res; 2003; 61():395-418. PubMed ID: 14714438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization.
    Chávez JH; Silva JR; Amarilla AA; Moraes Figueiredo LT
    Biologicals; 2010 Nov; 38(6):613-8. PubMed ID: 20817489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the RepliVax platform for replication-defective flavivirus vaccines.
    Rumyantsev AA; Giel-Moloney M; Liu Y; Gao QS; Zhang ZX; Catalan J; Frolov I; Almond J; Kleanthous H; Pugachev KV
    Vaccine; 2011 Jul; 29(32):5184-94. PubMed ID: 21620917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.